Familial hyperinsulinism is defined as an instance of hyperinsulinism caused by an inherited change in an individual's genome. This packet does not provide a certified causative gene list or inheritance pattern for the condition as a whole. Similarly, no molecular mechanism is certified in this packet. The packet does include ClinVar data noting a small number of pathogenic and likely pathogenic single nucleotide variants recorded in relevant databases, but no specific genes or hotspot variants are certified for this condition in the supplied gene fields. One recognized subtype, hyperinsulinism due to INSR deficiency, is described separately in expert literature and involves the insulin receptor, but gene names for the broader familial hyperinsulinism category are not certified in this packet and cannot be stated here.

This packet does not provide certified diagnostic methods, biomarker thresholds, or testing hierarchies for familial hyperinsulinism as a whole. Newborn screening status is also not certified in this packet. For the subtype INSR-related severe insulin resistance syndrome, expert review describes a diagnostic approach that includes clinical findings such as intrauterine growth restriction, distinctive facial features, hypotonia, and developmental delay, alongside laboratory assessment. That expert review notes that specific clinical, laboratory, and molecular findings inform the diagnosis of that subtype, but those criteria apply to the subtype and should not be generalized to all forms of familial hyperinsulinism. No broader diagnostic criteria, differential diagnosis framework, or confirmation requirements are certified in this packet for familial hyperinsulinism overall.

This packet does not include certified foundational therapies or FDA-approved treatments for familial hyperinsulinism as a whole. No orphan drug designations are listed in this packet. For the subtype INSR-related severe insulin resistance syndrome, expert review notes there is no cure, and that supportive care aimed at improving quality of life and reducing complications has been described, including nutritional management and glucose monitoring approaches. That same expert review discusses two therapies used in individuals with that subtype based on clinical experience and case series, but notes the absence of controlled trials; these details pertain specifically to that subtype. Treatment coverage for familial hyperinsulinism as a broader category is not certified in this packet.

Certified natural history or prognosis data for familial hyperinsulinism as a whole is not available in this packet. For the subtype INSR-related severe insulin resistance syndrome, expert review notes that the condition encompasses a phenotypic continuum ranging from more severe to milder presentations, and that fewer than 100 individuals had been identified with that subtype at the time of that review. Prognosis details specific to the broader familial hyperinsulinism category, including disease course, life expectancy, or long-term outcomes, are not certified here and cannot be described.

Several certified active clinical trial records are present for familial hyperinsulinism and related conditions. One Phase 3 trial sponsored by Zealand Pharma (NCT03941236) is evaluating the long-term safety and efficacy of dasiglucagon in children with congenital hyperinsulinism; this trial is active but not currently recruiting, with a projected completion date in late 2026. Two additional recruiting trials are examining imaging approaches: a Phase 2 study (NCT04205604) sponsored by Miguel Pampaloni is investigating 18Fluoro-LDOPA PET imaging for detecting and localizing focal congenital hyperinsulinism, and a Phase 1 study (NCT02021604) sponsored by Cook Children's Health Care System is evaluating Fluorodopa F 18 in congenital hyperinsulinism and insulinoma, with completion projected in 2028. Active clinical trials for this condition are listed on ClinicalTrials.gov.